$-0.15
(Market cap
$833 Mln
Revenue (TTM)
$80 Mln
P/E Ratio
--
P/B Ratio
228.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.3
-
Debt to Equity
-0.9
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
92,609,516
8 Years Aggregate
CFO
$-324.23 Mln
EBITDA
$-558.30 Mln
Net Profit
$-538.79 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MeiraGTx Holdings PLC (MGTX)
| 14.0 | -7.7 | 22.9 | 43.4 | 3.9 | -9.8 | -- |
|
BSE Sensex
| -12.6 | -4.3 | -4.6 | -10.3 | 5.7 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
MeiraGTx Holdings PLC (MGTX)
| 30.5 | 7.7 | -72.5 | 56.8 | -24.4 | 107.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MeiraGTx Holdings PLC (MGTX)
|
9.1 | 833.5 | 79.8 | -120.5 | -132.8 | -- | -- | 228.3 |
| 1.7 | 70.3 | 0.0 | -7.6 | -- | -- | -- | 5.4 |
Shareholding Pattern
View DetailsAbout MeiraGTx Holdings PLC (MGTX)
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large... degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York. Read more
-
CEO, President & Director
Dr. Alexandria Forbes Ph.D.
-
CEO, President & Director
Dr. Alexandria Forbes Ph.D.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MeiraGTx Holdings PLC (MGTX)
What is the current share price of MeiraGTx Holdings PLC (MGTX) Today?
The share price of MeiraGTx Holdings PLC (MGTX) is $9.06 (NASDAQ) as of 10-Jun-2026 11:40 EDT. MeiraGTx Holdings PLC (MGTX) has given a return of 3.93% in the last 3 years.
What is the current PB & PE ratio of MeiraGTx Holdings PLC (MGTX)?
Since, TTM earnings of MeiraGTx Holdings PLC (MGTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.57
|
-109.79
|
|
2024
|
-2.88
|
6.29
|
|
2023
|
-4.68
|
2.85
|
|
2022
|
-2.26
|
2.49
|
|
2021
|
-13.13
|
5.63
|
What is the 52 Week High and Low of MeiraGTx Holdings PLC (MGTX)?
The 52-week high and low of MeiraGTx Holdings PLC (MGTX) are Rs 11.85 and Rs 6.07 as of 10-Jun-2026.
What is the market cap of MeiraGTx Holdings PLC (MGTX)?
MeiraGTx Holdings PLC (MGTX) has a market capitalisation of $ 833 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MeiraGTx Holdings PLC (MGTX)?
Before investing in MeiraGTx Holdings PLC (MGTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.